GLP 1 News and Research

RSS

UB study creates new awareness for diabetics who are at risk for dehydration

Some drugs used to treat diabetes mimic the behavior of a hormone that a University at Buffalo psychologist has learned controls fluid intake in subjects. The finding creates new awareness for diabetics who, by the nature of their disease, are already at risk for dehydration.

12 Dec 2014

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

10 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

CHMP approves Victoza for use in adults with type 2 diabetes, moderate renal impairment

The Committee for Medicinal Products for Human Use today issued a positive opinion for the use of Victoza (liraglutide) in adults with type 2 diabetes and moderate renal impairment.

25 Nov 2014

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options.

28 Oct 2014

Economic impact of hypoglycaemia: an interview with Dr Klaus Henning Jensen

Hypoglycaemia is the term used to describe a lower than normal blood sugar level. There are a number of things that actually need to be formally defined in order for a hypoglycaemic episode to be diagnosed.

26 Oct 2014

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows.

15 Sep 2014

Acidity sensor helps to estimate dynamics of insulin production

Many human metabolic functions only run smoothly if the acid level in the body remains neutral and stable. For humans, normal blood pH values lie between 7.35 and 7.45. By way of comparison, an empty stomach is extremely acidic, with a pH value of 1.5.

12 Aug 2014

Whey protein drink can control erratic glucose levels associated with type 2 diabetes

Blood sugar surges - after-meal glucose "spikes" - can be life threatening for the 29 million Americans with diabetes. Diabetic blood sugar spikes have been linked to cardiovascular disease, cancer, Alzheimer's disease, kidney failure, and retinal damage.

5 Aug 2014

GSK announces availability of once-weekly Tanzeum in pharmacies throughout the U.S.

GSK today announced that once-weekly Tanzeum (albiglutide), a prescription injectable treatment for type 2 diabetes in adults, as an adjunct to diet and exercise, is now available in pharmacies throughout the U.S.

29 Jul 2014

Medical treatment guidelines for diabetes

Medical treatment guidelines are suggestions that international organizations such as the American Diabetes Association, the European Society for the Study of Diabetes and the American Association of Clinical Endocrinologists, used to set the tone in the control of the disease and how to apply a better therapy, depending on the physical condition of the person.

10 Jul 2014

BINDER ultra low temperature freezer provides high safety for biological samples

In the field of cell biology in particular, a wide variety of samples including nucleic acid or protein samples have to be preserved for longer periods of time. At temperatures down to – 86°C, samples often remain frozen for several weeks up to several years. 100% reliability of the cooling system is essential. Otherwise, any interruption could result in the complete loss of the research results, requiring the results to be recreated, which costs time and money.

From BINDER GmbH 3 Jul 2014

Study reveals surprising relationships between diet and release of hormones that suppress eating

By comparing how gut microbes from human vegetarians and grass-grazing baboons digest different diets, researchers have shown that ancestral human diets, so called "paleo" diets, did not necessarily result in better appetite suppression.

20 May 2014

Isis Pharmaceuticals reports positive data from ISIS-GCGRRx Phase 2 study in patients with type 2 diabetes

Isis Pharmaceuticals, Inc. announced today positive data from a Phase 2 study of ISIS-GCGRRx in patients with type 2 diabetes uncontrolled on stable metformin therapy.

14 May 2014

Patients with Parkinson's disease show improvements after exenatide therapy

Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.

9 May 2014

FDA approves GSK's Tanzeum as once-weekly treatment for type 2 diabetes

GlaxoSmithKline plc today announced that the US Food and Drug Administration has approved Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

16 Apr 2014

Common treatment for type 2 diabetes could cause longer-than-normal periods of hypoglycemia

Researchers at the University of Adelaide have discovered that a common treatment for people with type 2 diabetes could cause longer-than-normal periods of the low blood sugar reaction hypoglycemia, which may result in increased health risks to people with diabetes.

9 Apr 2014

Adocia announces positive final results for first clinical trial of BioChaperone Combo

Adocia announces today positive final results for the first clinical trial on its innovative formulation combining insulin analog glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

20 Mar 2014

New sweetener from tequila plant may aid diabetes, weight loss

A sweetener created from the plant used to make tequila could lower blood glucose levels for the 26 million Americans and others worldwide who have type 2 diabetes and help them and the obese lose weight, researchers said here today.

18 Mar 2014

DCR enters into agreement with Pyxant Labs for early clinical trials

DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, announced today that it has entered into an agreement through which Pyxant Labs Inc. will provide bioanalytical laboratory services for DCR's early clinical trials.

12 Feb 2014